» Articles » PMID: 35936987

MiR-623 Targets Metalloproteinase-1 and Attenuates Extravasation of Brain Metastatic Triple-Negative Breast Cancer Cells

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Most breast cancer-related deaths result from metastasis. Understanding the molecular basis of metastasis is needed for the development of effective targeted and preventive strategies. Matrix metalloproteinase-1 (MMP1) plays an important role in brain metastasis (BM) of triple-negative breast cancer (TNBC) by promoting extravasation of cancer cells across the brain endothelium (BE). MMP1 expression is controlled by endogenous microRNAs. Preliminary bioinformatics analysis has revealed that miR-623, known to target the 3'UTR of MMP1, is significantly downregulated in brain metastatic tumors compared to primary BC tumors. However, the involvement of miR-623 in MMP1 upregulation in breast cancer brain metastatic cells (BCBMC) remains unexplored. Here, we investigated the role of miR-623 in MMP1 regulation and its impact on the extravasation of TNBC cells through the BE in vitro.

Materials And Methods: A loss-and-gain of function method was employed to address the effect of miR-623 modulation on MMP1 expression. MMP1 regulation by miR-623 was investigated by real-time PCR, western blot, luciferase and transwell migration assays using an in vitro human BE model.

Results: Our results confirmed that brain metastatic TNBC cells express lower levels of miR-623 compared with cells having low propensity to spread toward the brain. miR-623 binds to the 3'-untranslated region of MMP1 transcript and downregulates its expression. Restoring miR-623 expression significantly decreased MMP1 expression, preserved the endothelial barrier integrity, and attenuated transmigration of BCBMC through the BE.

Conclusion: Our study elucidates, for the first time, the crucial role of miR-623 as MMP1 direct regulator in BCBMC and sheds light on miR-623 as a novel therapeutic target that can be exploited to predict and prevent brain metastasis in TNBC. Importantly, the presents study helps in unraveling a brain metastasis-specific microRNA signature in TNBC that can be used as a guide to personalized metastasis prediction and preventive approach with better therapeutic outcome.

Citing Articles

Crosstalk between breast cancer-derived microRNAs and brain microenvironmental cells in breast cancer brain metastasis.

Khan M, Wong G, Zhuang C, Najjar M, Lo H Front Oncol. 2024; 14:1436942.

PMID: 39175471 PMC: 11338853. DOI: 10.3389/fonc.2024.1436942.


Exosomes Interactions with the Blood-Brain Barrier: Implications for Cerebral Disorders and Therapeutics.

Osaid Z, Haider M, Hamoudi R, Harati R Int J Mol Sci. 2023; 24(21).

PMID: 37958619 PMC: 10648512. DOI: 10.3390/ijms242115635.


Insights into the Molecular Mechanisms Mediating Extravasation in Brain Metastasis of Breast Cancer, Melanoma, and Lung Cancer.

Alsabbagh R, Ahmed M, Alqudah M, Hamoudi R, Harati R Cancers (Basel). 2023; 15(8).

PMID: 37190188 PMC: 10137309. DOI: 10.3390/cancers15082258.


Molecular Heterogeneity of the Brain Endothelium.

Alnaqbi N, Mohammad M, Hamoudi R, Mabondzo A, Harati R Curr Issues Mol Biol. 2023; 45(4):3462-3478.

PMID: 37185751 PMC: 10136751. DOI: 10.3390/cimb45040227.


Insights into Exosome Transport through the Blood-Brain Barrier and the Potential Therapeutical Applications in Brain Diseases.

Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111328 PMC: 10144189. DOI: 10.3390/ph16040571.

References
1.
Zhou B, Zhu H, Luo H, Gao S, Dai X, Li Y . MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. Biomed Pharmacother. 2017; 87:412-418. DOI: 10.1016/j.biopha.2016.12.080. View

2.
Xing F, Sharma S, Liu Y, Mo Y, Wu K, Zhang Y . miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α. Oncogene. 2015; 34(37):4890-900. PMC: 4530094. DOI: 10.1038/onc.2014.412. View

3.
Winer A, Adams S, Mignatti P . Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther. 2018; 17(6):1147-1155. PMC: 5984693. DOI: 10.1158/1535-7163.MCT-17-0646. View

4.
Harati R, Mabondzo A, Tlili A, Khoder G, Mahfood M, Hamoudi R . Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells. Breast Cancer Res Treat. 2021; 187(3):695-713. DOI: 10.1007/s10549-021-06255-y. View

5.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View